NewsRoom Articles - Page 136 of 217

WednesdayNov 24, 2021 9:30 am

Study Investigates Influence of Ethnicity on Surviving Brain Tumors

New research has found that white British individuals who have been diagnosed with a malignant brain tumor have a higher risk of mortality than those from other ethnicities. The research’s findings were presented at the NCRI Festival. The study assessed the influence of an individual’s ethnicity on their rate of survival of a brain tumor. The researchers found that individuals who are classified under other ethnic groups had 30% lower chances of mortality in one year after being diagnosed with a malignant brain tumor. For the study, Hiba Wanis, a research assistant at King’s College London’s Centre for Cancer, Society…

TuesdayNov 23, 2021 9:30 am

Data Analytics Finds Disparities in Pregnancy Outcomes

Data analytics shows that ethnic and racial minority patients with systemic lupus erythematosus are disproportionately affected when it comes to pregnancy outcomes, despite the improvements seen over the last couple of years. In a press release, Bella Mehta, a rheumatologist at Hospital for Special Surgery and the lead author of a recent study, stated that these improvements were more apparent in some groups in comparison to others, explaining that Hispanics and African Americans still had poor pregnancy outcomes. Mehta noted that more research was needed to determine where resources were required to improve care and access for these patients. For…

MondayNov 22, 2021 9:30 am

Researchers Identify Molecular Mechanism Controlling the Development of Chronic Pain

Chronic pain is a huge problem that affects more than 1.5 billion individuals across the globe. It is defined as persistent pain that lasts anywhere between a couple of weeks to years. This pain usually evolves from acute pain that is caused by tissue damage owing to an injury or surgery. Researchers consider nerve damage to be a crucial factor in the transition to chronic pain. However, the events underlying the emergence of chronic pain hadn’t previously been discovered — until now. New research from the University of California, Irvine has found the molecular mechanisms that control the transition from…

MondayNov 22, 2021 8:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Excited for Seamless Phase 2/3 Clinical Research as Dr. Matthew Johnson Presents Interim Results of Current Smoking Cessation Study at the Psychedelic Medicine Business Event: Wonderland

Dr. Matthew Johnson discussed psilocybin for tobacco smoking cessation at this year’s Psychedelic Medicine Business Event: Wonderland, in Miami He shared preliminary findings from his recent study on substance use disorder, along with the participants’ feedback on their experience Dr. Johnson, along with Mydecine, are set to embark on their clinical study utilizing MYCO-001 for smoking cessation, set to commence in early 2022, building on the success of this recent study Mydecine is also set to support Dr. Johnson’s concurrent NIDA grant-funded study through the provision of MYCO-001 for research Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), back in September…

MondayNov 22, 2021 8:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Updating Trial Protocols in Response to FDA Request as Tryp Prepares Synthetic Psilocybin Studies for Eating Disorder, Fibromyalgia Treatment

Pharmaceutical company Tryp Therapeutics is investigating the potential of synthetic psychedelic drug candidates to treat unmet medical needs The company is evaluating two drug products labeled TRP-8802 and TRP-8803 for treating fibromyalgia, phantom limb pain, complex regional pain syndrome and select eating disorders The company has filed its first two INDs with the FDA for planned Ph 2a clinical trials relating to fibromyalgia and eating disorder treatments In the wake of changes recommended by the FDA to the eating disorders trial, Tryp is in the process of updating its protocols and patient consent form to meet the FDA’s expectations Tryp…

FridayNov 19, 2021 9:30 am

Large Trial Finds Psilocybin Efficacious Against Depression

Compass Pathways recently released results from a phase 2b trial, which was focused on evaluating the effectiveness of psilocybin as a treatment for depression. The results, which were announced earlier last week, show that the psychedelic substance was highly effective as a treatment for treatment-resistant depression. For their study, the researchers recruited more than 200 sites in different locations in North America and Europe. This study was the largest double-blind randomized controlled trial on psilocybin, which is an active compound found in hallucinogenic mushrooms. The company stated that it observed a significant reduction in symptoms of depression in patients who…

FridayNov 19, 2021 8:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health

Company releases positive results from preclinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) (https://ibn.fm/0GSuV). This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of…

ThursdayNov 18, 2021 9:49 am

Study Explores Link Between Obstructive Sleep Apnea and COVID-19

Obstructive sleep apnea ("OSA") is a common sleep-related breathing disorder that causes individuals to repeatedly start and stop breathing while they sleep. There exist different types of sleep apnea, with the most common one being obstructive sleep apnea. Common symptoms of this particular type of sleep apnea include loud snoring, excessive daytime sleepiness, episodes of stopped breathing and awakening abruptly, which may be accompanied by choking or gasping. A new study has found that patients with COVID-19 who suffer from obstructive sleep apnea have longer hospital stays and higher mortality rates when compared to patients with the coronavirus who don’t…

ThursdayNov 18, 2021 8:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Offers ‘First-of-a-Kind’ Device in Growing CGM Market

The global continuous glucose monitoring devices market size is expected to reach $19.04 billion in 2028 The increasing prevalence of diabetes, rising focus on preventive care are significant factors in the steady revenue growth Nemaura Medical’s sugarBEAT device allows individuals to make adjustments to diet and activity that can significantly change their lives According to a recent Reports and Data release, the global consumer monitoring (“CGM”) devices global market is forecast to see notable growth in the coming years (https://ibn.fm/LhWNO). Key companies operating in the space, including Nemaura Medical (NASDAQ: NMRD), are ideally positioned to benefit from that growth as they work…

WednesdayNov 17, 2021 1:22 pm

Mental Health Conditions, IBS Could Have Shared Origins

Irritable bowel syndrome (“IBS”) is a condition that affects one in every ten individuals globally. Its symptoms include bowel dysfunction and bloating and abdominal pain among others, which can significantly impact an individual’s life. Before a diagnosis can be made, clinicians usually consider the possibility of other ailments, including bowel cancer and Crohn’s disease. IBS is common in individuals who are prone to anxiety. While its causes aren’t well understood, a group of researchers recently discovered some genes that offer leads into its origin. The group was made up of more than 40 institutions, with the research being coordinated by…